Paracetamol Aurobindo is a widely available medicine used to provide symptomatic support in situations of acute discomfort. As a recognized analgesic and antipyretic agent, its therapeutic application is relevant for easing mild to moderate pain and reducing fever across various conditions.

Relief from Acute and Episodic Painful Discomfort

Paracetamol Aurobindo is commonly used to provide symptomatic relief from mild to moderate acute pain across various domains. This includes managing discomforts such as common headaches, dental pain, muscle aches, and pain associated with the menstrual cycle (dysmenorrhoea). By addressing these acute, short-term manifestations, it offers supportive relief that provides support that helps ease the overall symptom burden and supports general well-being during symptomatic phases.

Management of Fever and Systemic Symptoms

The medication is commonly used for its antipyretic benefit, playing a role in managing an elevated body temperature (fever) often accompanying seasonal illnesses like the common cold and flu-like symptoms. Applied in these contexts, it helps manage the systemic discomfort and body aches that cluster with fever, assisting with symptomatic management in contexts involving temporary physiological imbalance.

Quick Fact: Relief for Mild to Moderate Pain and Fever

Regulatory References

1. NIH MedlinePlus overview

The eligibility profile for Paracetamol Aurobindo is defined by specific regulatory criteria regarding absolute prohibition, age, and existing health conditions.

Who Cannot Use This Medicine

The medicine is contraindicated and must not be used by individuals with known hypersensitivity to paracetamol or any of the excipients. Absolute prohibition also applies to patients diagnosed with severe active liver disease and those concurrently taking any other medicinal product that contains paracetamol.

Age and Conditional Eligibility

Use is established for adults and adolescents aged 16 years and over. The 500 mg tablet strength is not recommended for children under 10 years because the dosage is unsuitable for that age range.

Use is restricted and requires caution for patients with moderate to severe renal or hepatic insufficiency (impaired kidney or liver function). Caution is also noted for patients with risk factors like non-cirrhotic alcoholic liver disease or conditions causing glutathione depletion.

For pregnant women, use is permitted at the lowest effective dose when clinically necessary. The medicine is generally not contra-indicated during breastfeeding.

The official regulatory interaction profile for Paracetamol Aurobindo defines drug and substance combinations that alter exposure, potentiate toxicity, or affect co-administered therapies.

Interactions Affecting Exposure and Toxicity

Co-administration with any other medicine containing Paracetamol is strictly restricted by regulatory authorities to prevent accidental overdose and subsequent liver damage. Interactions that modify Paracetamol plasma levels include Probenecid, which reduces clearance leading to increased Paracetamol concentrations, and Metoclopramide or Domperidone, which increase the rate of absorption. Conversely, Cholestyramine reduces Paracetamol absorption and requires a mandated timing separation of at least one hour during co-administration.

The risk of hepatotoxicity is officially noted to be increased by chronic, excessive alcohol consumption and co-administration with hepatic enzyme inducers such as Phenytoin, Rifampicin, and the herbal product St. John's Wort. Additionally, Paracetamol may potentiate the haematological toxicity of Zidovudine and increase the concentration of Chloramphenicol.

Anticoagulant and Population-Specific Interactions

A specific pharmacodynamic interaction is documented with oral anticoagulants (Coumarins/Warfarin), where prolonged, regular daily use enhances the anticoagulant effect. Population-specific cautions also exist: Paracetamol intake with Flucloxacillin has been associated with High Anion Gap Metabolic Acidosis (HAGMA) in patients with pre-existing risk factors like severe renal impairment or malnutrition.

Paracetamol's mechanism of action is primarily central, exerting effects within the Central Nervous System (CNS). It is understood to act as a relatively weak inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-2 and a potential COX-3 variant. This interaction is concentration-dependent and is believed to be modulated by peroxides present at sites of inflammation. The inhibition of COX activity modulates the synthesis of prostaglandins (PG), which are local lipid mediators. The reduced PG synthesis in the hypothalamus, the brain region responsible for thermoregulation, leads to a subsequent resetting of the thermostatic set-point, promoting heat dissipation through peripheral vasodilation and sweating. Furthermore, the central COX inhibition reduces PG-mediated sensitization of pain-conducting neurons. It is also proposed to interact with the endocannabinoid system by modulating N-arachidonoylphenolamine (AM404) reuptake, which may contribute to its central activity.

The administration of Paracetamol Aurobindo 500 mg tablets is based on specific parameters. The approved route of administration is oral through swallowing the tablet whole with a liquid. Guidelines specify that the medicine can be taken with or without food, although administration without food may result in a faster onset of action.

For adults and adolescents weighing 50 kg or more, the standard single dose ranges from 500 mg to 1000 mg. The dosing schedule is structured around a mandatory minimum interval of four hours between administrations. The total dose administered must not exceed 4000 mg (4 grams) within any 24-hour period, a critical limit. This core pattern dictates that the medicine is used on an intermittent, as-needed basis rather than on a fixed schedule.

Instructions also establish constraints for the duration of continuous use. Standard usage involves short-term use, typically not to exceed three days for fever or five days for pain, unless otherwise directed. Furthermore, use is subject to adjustments for certain populations: individuals with documented renal impairment must prolong the minimum interval between doses, and patients with chronic hepatic impairment or those under 50 kg are required to consider a reduced maximum daily dose to comply with established parameters. A key procedural restriction is the prohibition of concurrent administration with any other product containing paracetamol.

Research evidence / Overview of studies for Paracetamol Aurobindo

Evidence for use in Mild to Moderate Acute Pain

Research examining Paracetamol was applied in studies exploring how physical discomfort changes over time, primarily through extensive Randomized Controlled Trials (RCTs) and Systematic Reviews. These studies evaluated outcomes related to patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning. For certain conditions associated with acute or disruptive episodes, such as post-operative pain and the discomfort of osteoarthritis, the findings describe patterns observed in the studies with an evidence designation of High. For other conditions, evidence quality varies across studies, and some trials did not consistently report measurable differences in patient-reported outcomes.

Evidence for use in Fever Reduction (Antipyresis)

Paracetamol was studied for its role in managing outcomes related to systemic or functional imbalance associated with an elevated body temperature. Core evidence includes Randomized Controlled Trials that assessed this therapeutic area, focusing on change from baseline in body temperature and the duration of fever control in febrile children and adults. The findings generally describe patterns observed in the studies related to outcomes related to systemic or functional imbalance, which contributes to the broader evidence landscape with an evidence designation of High. Scientific literature suggests a relative paucity of modern, large-scale RCTs focused exclusively on this profile in the adult population.

Research Gaps and Consistency

The majority of controlled clinical trial data was observed in settings over intervals that are generally short-term. Consequently, there is limited information for long-term outcomes, and long-term effects are not fully established regarding repeated daily use. The available research provides context but not individual predictions. While the evidence was observed in some studies to have a High designation for specific acute conditions, data for certain groups remain insufficient, and subgroup findings are uncertain for special populations like older adults.

Key Studies & References Feverish illness in children: Assessment and initial management in children younger than 5 years (NICE Clinical Guideline)

Common questions about Paracetamol Aurobindo (FAQ)

Q: How quickly is Paracetamol Aurobindo expected to start working?

Peak blood concentrations of the active ingredient are typically observed between 10 and 60 minutes following oral administration.

This range indicates the period when the body has absorbed the highest concentration of the medicine according to regulatory documents.

Q: What is the typical duration of the pain relief from one dose?

The active substance has a plasma half-life, which is the time it takes for half of the substance to be eliminated, of approximately one to three hours.

Official regulatory documents structure the standard intermittent dosing around a minimum interval of four hours between administrations.

Q: Are there any specific side effects that affect the digestive system?

Clinical data indicates that gastrointestinal effects are commonly reported side effects for this medicine.

These effects can include nausea, vomiting, abdominal pain, diarrhea, and constipation.

Q: Does official information indicate Paracetamol Aurobindo can cause drowsiness?

According to the official Summary of Product Characteristics, the active ingredient has no known influence on the ability to drive or operate heavy machinery.

The medicine is not typically associated with causing drowsiness or sedation.

Q: Are there known interactions with common over-the-counter supplements?

Information regarding specific interactions with common non-herbal over-the-counter supplements is generally lacking in regulatory documents.

However, official labeling does include warnings about taking this medicine with the herbal product St. John’s Wort.

Q: Is it safe to use Paracetamol Aurobindo with blood pressure medication? (Informational)

The regulatory interaction profile lists cautions for several specific medicines, such as certain anticoagulants.

However, official documents do not specifically list general classes of blood pressure medication as having a formal contraindication or required precaution for informational purposes.

Q: Can people with high blood pressure use Paracetamol Aurobindo?

Official regulatory documents list specific contraindications, primarily related to severe active liver disease and known hypersensitivity to the active ingredient.

High blood pressure is not cited as a contraindication in the eligibility profile.

Q: Are there any special considerations for older adults using this medicine?

Mandatory dosage adjustments are officially required for patients with documented renal (kidney) or hepatic (liver) impairment.

However, specific mandatory dosage adjustments for the general older adult population are not explicitly required solely based on age, unless those underlying risk factors are present.

Q: What does the official labeling say about taking this medicine if a dose is missed?

Official guidance for a missed dose is to avoid taking a double dose to try and compensate.

Instead, the official guidance states to omit the missed dose entirely and continue with the next scheduled dose as originally planned.

Q: Does the medicine contain common allergens like gluten or lactose?

The patient information leaflet provides a full list of excipients (non-active ingredients) in the formulation.

The formulation typically does not include common allergens like lactose or gluten.

Q: Is there a known risk of dependence or tolerance development with Paracetamol Aurobindo?

The medicine is classified as a non-opioid analgesic, a class of pain reliever that acts differently from opioids.

Due to this classification, the risks of physical dependence or tolerance development are not cited in its official labeling.

Q: How is the strength of Paracetamol Aurobindo typically measured and what does it indicate?

The strength of the medicine is consistently measured in milligrams (mg).

This measurement represents the exact mass of the active ingredient, paracetamol, contained within a single tablet or dose.

Q: Does Paracetamol Aurobindo affect the results of any common laboratory tests?

Yes, official regulatory warnings indicate that the active ingredient may affect the results of certain laboratory tests.

This includes tests used to measure blood glucose and serum concentrations of certain liver enzymes.

Q: Are there any documented cases of Paracetamol Aurobindo affecting fertility?

Official regulatory information indicates that conventional studies using the accepted scientific standards for evaluating toxicity to reproduction and development are not available for the medicine.

Q: What are the signs of taking too much Paracetamol Aurobindo, as described in official warnings?

Early signs and symptoms of taking too much medicine, often appearing within the first 24 hours, can include non-specific effects.

These may involve nausea, vomiting, abdominal pain, loss of appetite, and increased sweating.

Q: Can Paracetamol Aurobindo be cut or crushed? (Factual about formulation)

Official labeling for the tablet form often indicates a score or breakline on the tablet itself.

This physical characteristic means that the tablet can be divided into equal halves.

Q: What non-active ingredients are included in Paracetamol Aurobindo formulations?

The formulation includes the active substance plus a set of excipients, or non-active ingredients.

These typically include pregelatinised starch (maize), sodium metabisulphite, stearic acid, and magnesium stearate.

Q: Does Paracetamol Aurobindo help with inflammation?

Regulatory documents describe the medicine primarily as a strong analgesic (pain reliever) and antipyretic (fever reducer).

It is noted as having only weak anti-inflammatory properties, meaning it does not primarily target swelling or inflammation in the same way as other drug classes.

Q: What information is available about people with diabetes using this drug?

The active ingredient in this medicine may interfere with certain laboratory tests related to blood analysis.

This includes the glucose oxidase method, which is specifically used for blood glucose measurement.

Q: Are there specific warnings about driving or operating machinery after taking Paracetamol Aurobindo?

Official labeling explicitly states that paracetamol has no known influence on the ability to drive or operate heavy machinery.

Therefore, specific warnings regarding these activities are not typically required for this medicine.

Q: Is there any research on the effect of Paracetamol Aurobindo on mood or sleep patterns?

Clinical data collected on this class of medicine has included reports of certain psychiatric side effects.

These can include insomnia (difficulty sleeping) and anxiety as commonly observed events.

Q: Why is the dosage often described in milligrams (mg)?

Dosage is consistently expressed in milligrams (mg) because this is the universally recognized scientific unit of measurement for the mass of the active pharmaceutical ingredient.

This measurement standard is essential for ensuring the accurate mass determination of the active ingredient.

Q: What is the distinction between this drug and similar acetaminophen products from different manufacturers?

The key distinction is that Paracetamol Aurobindo is defined as a generic medicine distributed by Aurobindo Pharma.

This means its specific manufacturing source, quality controls, and the specific non-active ingredients used in the formulation may differ from those of other manufacturers' products.

Storage Requirements

Paracetamol Aurobindo tablets must be stored at a temperature not above 25 C to maintain product stability. To ensure protection from light and moisture, the medicine is required to be kept in its original package.

It is a mandatory safety instruction that this medicine must be kept out of the sight and reach of children at all times. Do not use the tablets past the expiration date printed on the packaging.

Disposal Instructions

Official regulatory guidelines state that any unused or expired Paracetamol Aurobindo and its waste material must be disposed of in accordance with local requirements.

Crucially, the medicine must not be thrown away via household waste or wastewater to prevent environmental contamination. Patients should consult their pharmacist for guidance on proper disposal methods.